GraÅ¼yna ChÅ‚oÅ„-Rzepa

List of Publications by Year
in descending order

40 papers	416 citations	840776 11 h-index	839539 18 g-index
41 all docs	41 docs citations	41 times ranked	458 citing authors

#	Article	IF	Citations
1	Design and synthesis of new anilide and benzylamide derivatives as potential multifunctional ligands with procognitive and antidepressant activity. PostÄ™py Polskiej Medycyny I Farmacji, 2022, 9, 1-8.	0.0	0
2	Pan-Phosphodiesterase Inhibitors Attenuate TGF-Î²-Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation. Pharmaceuticals, 2022, 15, 423.	3.8	4
3	Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases. Pharmaceutics, 2022, 14, 1090.	4.5	1
4	New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases. European Journal of Medicinal Chemistry, 2021, 209, 112854.	5.5	16
5	Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2021, 28, 1731-1745.	2.4	9
6	PK/PD Modeling of the PDE7 Inhibitorâ€”GRMS-55 in a Mouse Model of Autoimmune Hepatitis. Pharmaceutics, 2021, 13, 597.	4.5	4
7	Diabetic Theory in Anti-Alzheimerâ€™s Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors. Current Medicinal Chemistry, 2021, 28, 3535-3553.	2.4	2
8	A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties. Future Medicinal Chemistry, 2021, 13, 1497-1514.	2.3	2
9	Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2021, 28, 6082-6094.	2.4	2
10	Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128318.	2.2	7
11	Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. Bioorganic Chemistry, 2021, 117, 105409.	4.1	11
12	Comparative Assessment of the New PDE7 Inhibitor â€“ GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach. Pharmaceutical Research, 2020, 37, 19.	3.5	12
13	Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. European Journal of Medicinal Chemistry, 2020, 201, 112437.	5.5	19
14	A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-Î² Signaling and Activation of cAMP/PKA Signaling. International Journal of Molecular Sciences, 2020, 21, 4008.	4.1	28
15	Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2020, 27, 5351-5373.	2.4	10
16	Diabetic Theory in Anti-Alzheimerâ€™s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents. Current Medicinal Chemistry, 2020, 27, 6658-6681.	2.4	6
17	ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY OF NEW ANALOGUES OF HC-030031: A TRPA1 CHANNEL ANTAGONIST. Acta Poloniae Pharmaceutica, 2020, 77, 113-119.	0.1	1
18	Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling. European Journal of Pharmacology, 2019, 865, 172779.	3.5	13

#	Article	IF	Citations
19	Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies. Current Medicinal Chemistry, 2019, 26, 4885-4913.	2.4	7
20	Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia. Current Drug Targets, 2019, 20, 1652-1669.	2.1	10
21	Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2018, 146, 381-394.	5.5	37
22	In Vitro Biotransformation, Safety, and Chemopreventive Action of Novel 8-Methoxy-Purine-2,6-Dione Derivatives. Applied Biochemistry and Biotechnology, 2018, 184, 124-139.	2.9	10
23	Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain. European Journal of Medicinal Chemistry, 2018, 158, 517-533.	5.5	27
24	Determination of ligand efficiency indices in a group of 7Hâ€purineâ€2,6â€dione derivatives with psychotropic activity using micellar electrokinetic chromatography. Electrophoresis, 2018, 39, 2446-2453.	2.4	3
25	Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research. Current Drug Targets, 2018, 20, 122-143.	2.1	23
26	Structureâ€“5â€HT/D₂ Receptor Affinity Relationship in a New Group of 1â€Arylpiperazynylalkyl Derivatives of 8â€Dialkylaminoâ€3,7â€dimethylâ€1Hâ€purineâ€2,6(3H,7H)â€dione. Archiv Der Pharmazie, 2016, 349, 774-784.	4.1	2
27	Aminoalkyl Derivatives of 8â€Alkoxypurineâ€2,6â€diones: Multifunctional 5â€HT_{1A}/5â€HT₇ Receptor Ligands and PDE Inhibitors with Antidepressant Activity. Archiv Der Pharmazie, 2016, 349, 889-903.	4.1	9
28	Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1048-1062.	5.2	10
29	New Arylpiperazinylalkyl Derivatives of 8â€Alkoxyâ€purineâ€2,6â€dione and Dihydro[1,3]oxazolo[2,3â€f]purinedione Targeting the Serotonin 5â€HT_{1A}/5â€HT_{2A}/5â€HT₇ and Dopamine D₂ Receptors. Archiv Der Pharmazie, 2015, 348, 242-253.	4.1	6
30	N-(4-Arylpiperazinoalkyl)acetamide derivatives of 1,3- and 3,7-dimethyl-1H-purine-2,6(3H,7H)-diones and their 5-HT₆, 5-HT₇, and D₂ receptors affinity. Heterocyclic Communications, 2015, 21, 13-18.	1.2	6
31	Synthesis of 8-alkoxy-1,3-dimethyl-2, 6-dioxopurin-7-yl-substituted acetohydrazides and butanehydrazides as analgesic and anti-inflammatory agents. Heterocyclic Communications, 2015, 21, 273-278.	1.2	7
32	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT1A receptor functional profile. Bioorganic and Medicinal Chemistry, 2015, 23, 212-221.	3.0	31
33	Analgesic activity of new 8-methoxy-1,3-dimethyl-2,6-dioxo-purin-7-yl derivatives with carboxylic, ester or amide moieties. Pharmacological Reports, 2015, 67, 9-16.	3.3	8
34	Analgesic and anti-inflammatory activity of 7-substituted purine-2,6-diones. Pharmacological Reports, 2014, 66, 996-1002.	3.3	10
35	New 7-arylpiperazinylalkyl-8-morpholin-4-yl-purine-2,6-dione derivatives with anxiolytic activity â€“ Synthesis, crystal structure and structureâ€“activity study. Journal of Molecular Structure, 2014, 1067, 243-251.	3.6	10
36	7-3-Chlorophenypiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione as a serotonin receptor ligands with potential antidepressant activity. Pharmacological Reports, 2014, 66, 505-510.	3.3	12

#	Article	IF	Citations
37	New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation. Pharmacological Reports, 2013, 65, 15-29.	3.3	15
38	Structure-cardiovascular activity relationships in a group of new 8-alkylamino-1,3-dimethyl-7-(2-hydroxy-3-aminopropyl)-3,7-dihydro-1H-purine-2,6-diones. Pharmacological Reports, 2011, 63, 476-486.	3.3	3
39	7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT1A, 5-HT2A, and 5-HT7 serotonin receptor ligands. Bioorganic and Medicinal Chemistry, 2007, 15, 5239-5250.	3.0	21
40	Synthesis and cardiovascular activity of new 8-alkylamino-1,3-dimethyl-7-(2-hydroxy-3-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 Td (pip	0.3	1